COMMUNIQUÉS West-GlobeNewswire

VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001
25/09/2025
VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001 Japanese regulator, the PMDA, waived the requirement for a Phase 1 trial in Japanese subjects for lead asset VMX-C001, enabling it to go [...]
Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam
25/09/2025
- Total non-dilutive funding of up to USD 159 million upon completion of predefined milestones, including near-term committed funding of USD 6 million Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, [...]
Fagron announces the acquisition of UCP in North America and FDA inspection update
25/09/2025
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 25 September 2025 – 7:00 AM CET Fagron announces the acquisition of UCP in North America and FDA inspection update Fagron, the [...]
Les résultats semestriels confirment la pertinence de la stratégie de Roquette
25/09/2025
Les résultats semestriels confirment la pertinence de la stratégie de Roquette Roquette surperforme ses principaux marchés et enregistre des résultats solides au premier semestre dans des conditions de marché complexes [...]
Santhera Provides Update on Convertible Bond Issued on 23 September 2025
25/09/2025
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, September 25, 2025 – Santhera Pharmaceuticals (SIX: SANN) today provides the following update regarding its convertible bond announced on 23 September [...]
Press release: Sequana Medical announces H1 2025 results and provides business update
25/09/2025
Sequana Medical announces H1 2025 results and provides business update alfapump ® US commercialisation underway; Strengthened US reimbursement with CMS approval of NTAP “top-up” reimbursement; On track for at least 70 [...]
H1 25 Results Confirm the Relevance of Roquette’s Strategy
25/09/2025
H1 25 Results Confirm the Relevance of Roquette’s Strategy Roquette outperforms its key markets, delivering solid H1 results in current complex market conditions. Successful completion of the acquisition of IFF Pharma [...]
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
25/09/2025
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the pricing of its underwritten public [...]
Summary Notice of Proposed Settlement of Derivative Actions
25/09/2025
LEHI, Utah, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Owlet, Inc. (NYSE:OWLT) has released the following notice: IN THE UNITED STATES DISTRICT COURT FOR THE CENTRAL DISTRICT OF CALIFORNIA IN RE OWLET, INC. SHAREHOLDER [...]
MBX Biosciences Announces Pricing of Upsized Public Offering
25/09/2025
CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the [...]
Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients
25/09/2025
Sapu003 Designed to Overcome Limitations of Afinitor ® , FDA-Approved Oral Everolimus, Delivering Full Strength of Everolimus via Intravenous Injection AUSTRALIA, Sydney, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sapu Nano, [...]
Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients
25/09/2025
Sapu003 Designed to Overcome Limitations of Afinitor ® , FDA-Approved Oral Everolimus, Delivering Full Strength of Everolimus via Intravenous Injection AUSTRALIA, Sydney, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sapu Nano, [...]
Range Impact Announces $550,000 Capital Raise
24/09/2025
Cleveland, Ohio, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTCQB: RNGE) (“Range Impact” or the “Company”), a public impact investing company dedicated to acquiring, reclaiming and repurposing mine sites in [...]
Verano to Report Third Quarter 2025 Financial Results on October 29, 2025
24/09/2025
CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that it plans to release financial [...]
SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury
24/09/2025
Independent DSMB reports zero device-related safety issues Supports potential clinical benefit Trial sample size re-estimated to strengthen statistical power DENVER, Sept. 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical [...]
Precision Optics Schedules Fourth Quarter and Fiscal Year 2025 Conference Call for September 29, 2025
24/09/2025
GARDNER, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/ [...]
uniQure Announces $200 Million Proposed Public Offering
24/09/2025
LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced [...]
Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone
24/09/2025
GAITHERSBURG, Md., Sept. 24, 2025 (GLOBE NEWSWIRE) -- In recognition of several observances in September meant to keep the national opioid poisoning epidemic front and center, Emergent BioSolutions Inc. (NYSE: EBS) [...]
Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association
24/09/2025
IRVINE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will participate in a plenary [...]

Pages